Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE-CKD: Tirzepatide in Overweight/Obesity and Chronic Kidney Disease
NCT05536804Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of tirzepatide in chronic kidney disease (CKD), obesity, sponsored by Eli Lilly and Company. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on NCT05536804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536804.